ストックスクリーナーアプリを入手
90.14
1.36%
1.21
アフターアワーズ：
90.00
-0.14
-0.16%
前日終値:
$88.93
開ける：
$88.12
24時間の取引高:
1.09M
Relative Volume:
1.71
時価総額：
$5.73B
収益：
$434.41M
当期純損益:
$-128.05M
株価収益率:
-9.8085
EPS:
-9.19
ネットキャッシュフロー:
$-250.52M
1週間 パフォーマンス:
-3.27%
1か月 パフォーマンス:
-4.93%
6か月 パフォーマンス:
-14.32%
1年 パフォーマンス:
+7.16%
1日の値動き範囲:
$87.99
$90.99
1週間の範囲:
$86.02
$98.41
52週間の値動き範囲:
$72.24
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
名前
Blueprint Medicines Corp
セクター
電話
617-374-7580
住所
45 SIDNEY STREET, CAMBRIDGE, MA
BPMC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
90.14 | 5.73B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | 開始されました | JP Morgan | Overweight |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2024-05-06 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-08-21 | 繰り返されました | Needham | Buy |
| 2023-07-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-11-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-09-14 | 開始されました | Berenberg | Buy |
| 2022-07-08 | 開始されました | Oppenheimer | Outperform |
| 2022-06-27 | 開始されました | Wells Fargo | Underweight |
| 2022-06-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-06-01 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-01 | 開始されました | Citigroup | Neutral |
| 2022-02-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | アップグレード | Stifel | Hold → Buy |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-09-30 | 再開されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-11-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-02 | ダウングレード | Jefferies | Buy → Hold |
| 2020-10-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Equal Weight |
| 2020-03-17 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-11-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-09-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | 開始されました | Piper Jaffray | Neutral |
| 2019-08-15 | 再開されました | Raymond James | Mkt Perform |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2019-05-23 | 再開されました | Goldman | Buy |
| 2019-04-03 | 開始されました | Morgan Stanley | Overweight |
| 2018-09-25 | 開始されました | Leerink Partners | Outperform |
| 2017-12-11 | 繰り返されました | Goldman | Buy |
すべてを表示
Blueprint Medicines Corp (BPMC) 最新ニュース
Blueprint Medicines director Jeffrey Albers sells $1.35 million in stock - Investing.com India
Blueprint Medicines COO Christina Rossi sells $218,098 in shares By Investing.com - Investing.com Australia
Blueprint Medicines COO Christina Rossi sells $218,098 in shares - Investing.com
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus.com
Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,000 Shares - MarketBeat
Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of Stock - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Shares Down 3.6%What's Next? - MarketBeat
Blueprint Medicines Corporation Seeks Validation of 2024 Stockholder Actions Through Section 205 Action - Defense World
Blueprint Medicines' SWOT analysis: stock's potential in precision oncology - Investing.com
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
Geode Capital Management LLC Raises Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $169,639.94 in Stock - MarketBeat
Blueprint Medicines officer sells shares worth $169,635 - Investing.com
Blueprint Medicines officer sells shares worth $169,635 By Investing.com - Investing.com UK
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Barclays PLC - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat
Blueprint Medicines' SWOT analysis: stock outlook amid Ayvakit success - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by State Street Corp - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zimmer Partners LP Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Castleark Management LLC - MarketBeat
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting - Quantisnow
Holocene Advisors LP Sells 926,550 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Blueprint Medicines (FRA:2L9) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
Jacobs Levy Equity Management Inc. Buys 306,079 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines CEO Kate Haviland sells $227,304 in shares By Investing.com - Investing.com Australia
Blueprint Medicines CEO Kate Haviland sells $227,304 in shares - Investing.com
Erste Asset Management GmbH Purchases New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Down 5.3% in November - MarketBeat
The Manufacturers Life Insurance Company Has $13.88 Million Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Edgestream Partners L.P. - MarketBeat
Fred Alger Management LLC Sells 15,478 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Sells 316,913 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 5,132 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Eventide Asset Management LLC Grows Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Alkeon Capital Management LLC Has $66.50 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Citigroup Inc. - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
Intech Investment Management LLC Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Massachusetts Financial Services Co. MA Has $23.33 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Pitcairn Co. Has $954,000 Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Acquires New Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (FRA:2L9) EPS without NRI : €-4.43 (TTM As of Sep. 2024) - GuruFocus.com
Blueprint Medicines (FRA:2L9) Revenue per Share : €6.33 (TTM As of Sep. 2024) - GuruFocus.com
Blueprint Medicines (FRA:2L9) Operating Cash Flow per Share : €-3.56 (TTM As of Sep. 2024) - GuruFocus.com
Algert Global LLC Purchases 26,696 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Eagle Asset Management Inc. - MarketBeat
Blueprint Medicines Corp (BPMC) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):